Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 9 | 2022 | 756 | 0.880 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2021 | 14 | 0.790 |
Why?
|
| Lupus Nephritis | 4 | 2022 | 193 | 0.580 |
Why?
|
| Nephritis | 2 | 2019 | 37 | 0.570 |
Why?
|
| Kidney | 2 | 2016 | 945 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 503 | 0.380 |
Why?
|
| Child | 12 | 2022 | 6400 | 0.330 |
Why?
|
| Arthritis, Juvenile | 3 | 2015 | 70 | 0.320 |
Why?
|
| Remission Induction | 2 | 2021 | 111 | 0.310 |
Why?
|
| Antirheumatic Agents | 3 | 2021 | 58 | 0.300 |
Why?
|
| Rheumatology | 2 | 2015 | 46 | 0.250 |
Why?
|
| Nephrologists | 2 | 2021 | 7 | 0.250 |
Why?
|
| Rheumatologists | 2 | 2021 | 14 | 0.250 |
Why?
|
| Vasculitis | 1 | 2023 | 33 | 0.230 |
Why?
|
| src-Family Kinases | 1 | 2023 | 91 | 0.220 |
Why?
|
| Pediatricians | 1 | 2021 | 9 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2005 | 310 | 0.200 |
Why?
|
| Rituximab | 1 | 2021 | 61 | 0.200 |
Why?
|
| Adolescent | 9 | 2022 | 8903 | 0.190 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2020 | 3 | 0.190 |
Why?
|
| Panniculitis | 1 | 2020 | 7 | 0.190 |
Why?
|
| Interleukin-18 | 1 | 2020 | 16 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 1 | 2021 | 171 | 0.190 |
Why?
|
| Cooperative Behavior | 3 | 2019 | 235 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2020 | 32 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2022 | 222 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2023 | 384 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2015 | 342 | 0.170 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2021 | 266 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 8 | 0.160 |
Why?
|
| Behcet Syndrome | 1 | 2018 | 5 | 0.160 |
Why?
|
| Methimazole | 1 | 2018 | 9 | 0.160 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 10 | 0.160 |
Why?
|
| Retinal Artery | 1 | 2018 | 10 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 434 | 0.160 |
Why?
|
| Research | 1 | 2019 | 214 | 0.160 |
Why?
|
| Visual Acuity | 1 | 2018 | 236 | 0.150 |
Why?
|
| Biopsy | 2 | 2016 | 539 | 0.150 |
Why?
|
| Humans | 16 | 2023 | 68525 | 0.140 |
Why?
|
| Midwestern United States | 1 | 2015 | 36 | 0.130 |
Why?
|
| Specialization | 1 | 2015 | 66 | 0.130 |
Why?
|
| Nephrology | 1 | 2015 | 43 | 0.130 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 41 | 0.130 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 517 | 0.130 |
Why?
|
| Biomarkers | 2 | 2019 | 1593 | 0.130 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2264 | 0.120 |
Why?
|
| Data Collection | 1 | 2015 | 420 | 0.120 |
Why?
|
| Smartphone | 1 | 2014 | 69 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 285 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2015 | 403 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 514 | 0.110 |
Why?
|
| Mobile Applications | 1 | 2014 | 138 | 0.100 |
Why?
|
| Female | 9 | 2022 | 38015 | 0.100 |
Why?
|
| Male | 9 | 2022 | 37281 | 0.100 |
Why?
|
| Physicians | 1 | 2015 | 324 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2019 | 3185 | 0.090 |
Why?
|
| Age of Onset | 2 | 2022 | 188 | 0.080 |
Why?
|
| Pediatrics | 2 | 2016 | 341 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 442 | 0.070 |
Why?
|
| Dermatomyositis | 1 | 2005 | 31 | 0.070 |
Why?
|
| Dasatinib | 1 | 2023 | 17 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2798 | 0.050 |
Why?
|
| Neutrophils | 1 | 2023 | 204 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2021 | 31 | 0.050 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 32 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2453 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 392 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 2891 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 211 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2023 | 1199 | 0.050 |
Why?
|
| Dermatologists | 1 | 2019 | 5 | 0.040 |
Why?
|
| Neurologists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 648 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 32 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 948 | 0.040 |
Why?
|
| Antithyroid Agents | 1 | 2018 | 20 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2018 | 33 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 142 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2018 | 57 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2019 | 122 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 188 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 1030 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2016 | 126 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2019 | 403 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2016 | 248 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 238 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2019 | 659 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 2093 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 729 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1737 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 7264 | 0.020 |
Why?
|
| Logistic Models | 1 | 2007 | 1419 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.010 |
Why?
|
| Adult | 2 | 2014 | 21375 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5708 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 7028 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 21119 | 0.010 |
Why?
|